Epigenetics is the study of inherited changes in phenotype (appearance) or gene expression caused by mechanisms other than changes in the underlying DNA sequence. These changes may remain through cell divisions for the remainder of the cell’s life and may also last for multiple generations. However, there is no change in the underlying DNA sequence of the organism; instead, non-genetic factors cause the organism’s genes to behave (or “express themselves”) differently.

Proceeds from the financing will be used to advance the development of Constellation’s pipeline of compounds towards the clinic. These funds will also enable Constellation to continue applying its innovative epigenetics product engine to probe multiple classes of novel drug targets involved in chromatin regulation and disease.

About Constellation Pharmaceuticals
Constellation Pharmaceuticals is the leading biopharmaceutical company dedicated to the discovery and development of novel therapeutics in the emerging field of epigenetics, a new field of science that focuses on selective regulators of gene function and expression. The Company’s academic founders represent the core thought leaders in epigenetics and are responsible for numerous key advances in the field. Constellation Pharmaceuticals is located in Cambridge, Massachusetts. For more information, please visit the company’s website at .

The Company’s target customers are large employers, health plans and insurers, specialty care and disease management companies, provider health systems, pharmaceutical makers and clinical trial sponsors, pharmacy benefit managers, device makers, and consumer wellness retail and fitness brands. Customers may license Healthrageous’ core platform to design their own custom solution, or may purchase Healthrageous’ solutions off-the-shelf on a turn-key basis for deployment under their own brand or under the Company’s Healthrageous brand.

About the Company
Launched in 2010, Healthrageous, Inc. designs and delivers highly effective, personalized, interactive, motivational self-management solutions that help individuals shed unhealthy habits, improve their adherence to medical advice, and embrace healthy lifestyles. Healthrageous achieves its success by combining wireless biometric sensors, smart phones, individualized coaching, incentive programs and social network support in a real-time, interactive, feedback-rich experience that keeps individuals involved and motivated toward achieving their personal health and wellness goals. The company’s solutions are based on technologies developed at the Center for Connected Health, a division of Partners HealthCare, founded by Brigham and Women’s Hospital and Massachusetts General Hospital, teaching affiliates of Harvard Medical School. Healthrageous, Inc. is headquartered in Massachusetts.

About SiliconBlue
SiliconBlue Technologies is the first programmable logic start-up company in 20 years to ship products in volume production. The company offers a new class of ultra-low power, single-chip, SRAM FPGAs designed specifically for handheld consumer applications. Manufactured on TSMC’s 65nm LP (low power) CMOS process, the iCE65 mobileFPGA family meets the capacity, power, area, and price requirements for high-volume, battery-operated products such as Smart Phones, eReaders, mobile internet devices, and digital still cameras. Headquartered in Santa Clara, California, the company has a highly skilled team of programmable logic device (PLD) experts who have been instrumental in developing and patenting many of the leading programmable logic technologies in the market today.

Verdict: Avoid this service.

1and1 support is rather unhelpful. When you complain the best you get is a meaningless canned response from some call center in Philippines:

We apologize for this inconvenience that is causing you right now however, our admins are already informed about it and they are currently working on it to fix this issue and complete the maintenance as soon as possible. Your patience on this matter is highly appreciated.

These canned responses right out of script book were received hours after the problem has been resolved:

We sincerely apologize for the inconvenience it has caused you. Rest assured that our Administrators are already working on it. You may send an email to our Complaints Department

12 hours after the problem has been resolved:

We do apologize for this inconvenience. Rest assured that you would still be able to access your email account. Our administrators are working on this case to be resolved.

Instead of improving customer service the evil minds in charge of 1and1 perfectionize the art of venting out customer’s rage - after every complaint to support service you’ll be asked to provide your feedback in “Satisfied with our Service?” survey.

The financing will allow the company to accelerate the global launch of the company’s lead product, ViaMetrics-E™, a rapid, non-invasive procedure that is designed to enhance in vitro fertilization (IVF) outcomes; implement manufacturing and product enhancements; and complete its ongoing FDA clinical study. ViaMetrics-E aids in the identification of viable embryos having the greatest reproductive potential, thus improving pregnancy rates in IVF, and ultimately reducing the number of embryos transferred along with the complications and healthcare costs that accompany multiple births.

“We believe ViaMetrics-E meets a clear unmet medical need and is well-positioned to tap into the $4 billion global IVF market,” said James A. Datin, Executive Vice President and Managing Director of Safeguard Scientifics’ Life Sciences Group.

Metabolomics at Molecular Biometrics
Metabolomics is a complex scientific process that identifies and measures individual signals from many small molecular compounds produced during cellular metabolism. The company’s novel technology platform creates a ‘metabolomic profile’ or ‘fingerprint’ of an embryo’s potential viability, prior to possible embryo transfer in an IVF cycle. Metabolomic profiling provides a simultaneous evaluation of large numbers of biomarkers that reflect embryo development in culture media.

Molecular Biometrics developed a proprietary near infrared (NIR) biospectroscopy platform for its metabolomic applications. This technology rapidly measures the vibrational energy ‘signatures’ produced by small molecule functional groups, creating a unique profile of molecules that are descriptive of cellular function and viability. The signatures are further analyzed by proprietary bioinformatics, which evaluates the biological and chemical data produced by NIR biospectroscopy, using sophisticated computer and statistical techniques to distinguish between the often subtle differences that separate normal physiology from the onset or progression of disease, or an individual’s response to therapeutic intervention.

Working in collaboration with ALT Software, a leading supplier of 2D and 3D graphics, AMD is able to offer customers an alternative to custom programming by developing a standards-based parallel processing API, helping them to improve performance in embedded computing systems by leveraging the power of the graphics processor (GPU). For example, the GPU has become a standard hardware component in defense market, making it an ideal parallel processing solution.

Features:

• The ATI Radeon E4690 MXM features 512MB of on-board GDDR3 memory, 320 shader processors, a comprehensive set of display output options and adjustable system clocks for exacting power and performance requirements.
• As the industry’s only embedded graphics chip to offer support for both Microsoft DirectX® 10.1 and AMD’s Unified Video Decoder 2 (UVD 2), the ATI Radeon E4690 MXM enables competitive advantages for AMD’s embedded customers by providing outstanding graphics support coupled with high quality video playback performance.
• Incorporating ATI PowerPlayTM intelligent power management technology, the ATI Radeon E4690 MXM is designed to optimize power consumption and enable exceptional performance per Watt for power sensitive embedded applications.
• System designers have ultimate flexibility with a comprehensive selection of outputs including dual independent display controllers, integrated DisplayPortTM, integrated single & dual-link LVDS, integrated single & dual-link DVI/TMDS/HDMI and analogue outputs.
• Supported by ATI Stream technology, the ATI Radeon E4690 MXM can replace numerous system hardware components (e.g. FPGAs, DSPs etc.), helping to reduce overall system power, size, and cost.

“As the graphics requirements for embedded systems continue to increase, AMD has armed the ATI Radeon E4690 MXM with features that are important to our customers and done so within an industry-standard specification that helps simplify design, development and market delivery. Based on the successful ATI Radeon™ E4690 GPU, the ready-made ATI Radeon E4690 MXM solution provides the graphics performance, energy efficiency and reliability customers need. This, coupled with the module’s five year product life cycle, makes the ATI Radeon E4690 the easy answer for system designers looking to gain competitive advantage in the marketplace,” said Richard Jaenicke, director of Embedded Discrete Graphics for AMD.

“The ATI Radeon E4690 MXM module is an ideal solution for aerospace and defense industry. Its parallel processing capabilities open up a whole new range of applications including video surveillance, radar processing, target acquisition and synthetic vision. This module is ideal for manufacturers of embedded systems that require high-performance computing and advanced graphics,” says Dan Joncas, VP Sales ALT Software.

QD Vision’s first product, announced in 2009, is a Quantum Light™ optic for a new high- efficiency, high-color-quality LED lamp developed by Nexxus Lighting, Inc. (NASDAQ:NEXS), that combines the warmth and color of incandescent bulbs with the efficiency of LED technology. The power-saving lamp, expected to ship in the first quarter of 2010, can be directly installed in standard Edison sockets used by today’s incandescent bulbs. Meanwhile, QD Vision is actively working with several worldwide major manufacturers to design its Quantum Light™ optic into a number of SSL lamps and fixtures.

Founded in 2004 by a research team from MIT, QD Vision has raised a total of $33 million in venture capital financing.

“Ubuntu 9.10 Server Edition puts Ubuntu users at a unique advantage of being able to quickly and simply deploy and manage cloud environments. We strongly believe that businesses which are already embracing virtualized environments will take the next logical step to these self-service, super-efficient architectures and that Ubuntu Enterprise Cloud will be at the heart of that effort,” says Matt Zimmerman, CTO of Canonical.

Ubuntu Enterprise Cloud (UEC) is powered by software from Eucalyptus Systems, and provides an open source software infrastructure for implementing on-premise cloud computing. UEC makes it extremely easy and fast for system administrators to set up, deploy and manage a cloud environment. Users familiar with elastic compute environments will be able to build similar infrastructure behind their firewall, avoiding any regulatory and security concerns that prevent many enterprises from taking advantage of cloud environments.

Ubuntu Enterprise Cloud is preparing a store capability that will provide users with easy access to ready-to-deploy appliances in the UEC environment. A first preview of this store is available in Ubuntu 9.10, together with a sample appliance. It will demonstrate the solution to software vendors and additional appliances will be added after the release.

The core server product and kernel have also received significant attention in this release. MySQL 5.1 has been added. The directory stack and Single Sign On tools have been upgraded for improved directory integration. Django now ships as a fully supported framework enhancing web server options.

There have been numerous kernel improvements to better support both Xen (guest) and KVM (host and guest) virtualization, and to improve caching performance. Support for the USB 3.0 protocol has been included to support super speed transfer rates when devices become available. System management support has been extended through support for the WBEM (web-based enterprise management) protocols which open up support of Ubuntu environment to the most popular system management tools currently deployed in enterprises. Ubuntu’s own systems management tool, Landscape, has added a dedicated server to its hosted version allowing deployments to be managed entirely within the firewall and will fully support Ubuntu 9.10 Server Edition and Ubuntu Enterprise Cloud.

“The experience and knowledge we have gained during our tobacco field trial is laying the groundwork for planning and permitting activities for field trials in bioengineered, non-food oilseed and biomass crops producing PHA. We believe that our crop programs offer a number of commercialization options and hold significant potential. We are excited to continue to push this technology forward and believe it will ultimately support a diverse array of bioengineered, environmentally conscious and economically viable alternatives to petroleum-based products,” says Dr. Oliver Peoples, Chief Scientific Officer of Metabolix.